febit's HybSelect has been recognized as one of the winners of the "Top 10 Innovations of 2009" by The Scientist magazine. The company's automated sequence capture technology for highthroughput sequencing was selected due to its exceptional combinations of invention, vision and utility.
The Scientist gathered a panel of expert judges to evaluate a broad range of life science technologies and determined the best innovations to hit the life sciences market in 2009. The winners' list includes a variety of products that capture both intracellular and extracellular processes. HybSelect is a robust and automated method for selecting and enriching highvalue target regions from the genome that enables costeffective massively parallel sequencing.
"Next-Generation Sequencing (NGS) is an accurate and highperformance technology for diagnostics and has been limited by throughput, cost, data management and automation issues," said Peer Staehler, chief scientific officer of febit. "Instead of analyzing largesequence stretches of a single genome, researchers using HybSelect are now able to focus on targeted resequencing of interesting regions from many different patients in parallel."
HybSelect combines the advantages of microarraybased enrichment with patent protected microfluidic biochip technology and runs on the dedicated, highly automated instrument, the Geniom® RT Analyzer. It allows to conduct large scale clinical studies to identify SNPs and mutations as new biomarkers to receive statistically relevant data.
To read the full article of The Scientist please visit http://www.the-scientist.com/...
The Scientist gathered a panel of expert judges to evaluate a broad range of life science technologies and determined the best innovations to hit the life sciences market in 2009. The winners' list includes a variety of products that capture both intracellular and extracellular processes. HybSelect is a robust and automated method for selecting and enriching highvalue target regions from the genome that enables costeffective massively parallel sequencing.
"Next-Generation Sequencing (NGS) is an accurate and highperformance technology for diagnostics and has been limited by throughput, cost, data management and automation issues," said Peer Staehler, chief scientific officer of febit. "Instead of analyzing largesequence stretches of a single genome, researchers using HybSelect are now able to focus on targeted resequencing of interesting regions from many different patients in parallel."
HybSelect combines the advantages of microarraybased enrichment with patent protected microfluidic biochip technology and runs on the dedicated, highly automated instrument, the Geniom® RT Analyzer. It allows to conduct large scale clinical studies to identify SNPs and mutations as new biomarkers to receive statistically relevant data.
To read the full article of The Scientist please visit http://www.the-scientist.com/...
